Polycystic ovarian disease
- PMID: 6232474
Polycystic ovarian disease
Abstract
PIP: Polycystic ovarian disease (PCOD) was first described as a single disease by Stein and Leventhal in 1935, but now has been separated into several distinct entities, comprising a symptom complex. The most frequent presenting symptoms associated with PCOD are obesity, hirsutism, amenorrhea or anovulation, dysfunctional uterine bleeding, irregular menses, and infertility. The common finding of hirsutism in PCOD patients is a reflection of the hyperandrogenism resulting from elevation of all the androgens, including testosterone, androstenediol, dehydroepiandrostrone sulfate (DHEA-S), and androstenedione. Some patients with all the clinical features of PCOD can be shown, through appropriate testing, to have an attenuated form of classic congenital adrenal hyperplasia (CAH). Serum follicle stimulating hormone (FSH) levels are usually low or in the normal range, and serum luteinizing hormone (LH) levels are usually elevated in patients with PCOD, resulting in an altered LH/FSH ratio. Treatment for PCOD must be based on the needs and desires of the individual patient, and on the pathophysiology of the patient's particular abnormalities. When pregnancy is desired, ovulation induction with clomiphene is indicated. Clomiphene is a weak estrogen that induces a transient rise in serum LH and FSH, followed by a gonadotropic pattern similar to normal cycles. A 72% ovulation rate and a 41.8% conception rate have been reported after treatment with clomiphene. In patients who do not respond to clomiphene, or clomiphene with added human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG) can be used to induce ovulation, but the patient should be closely monitored for multiple ovulation, multiple pregnancy, or hyperstimulation syndrome. For patients not interested in conception, regular menstrual cyclicity can be restored and hyperandrogenism reduced with oral contraceptives (OCs).
Similar articles
-
Ovulatory disorders in women with polycystic ovary syndrome.Clin Obstet Gynaecol. 1985 Sep;12(3):605-32. Clin Obstet Gynaecol. 1985. PMID: 3933879 Review.
-
Evaluation and therapy of polycystic ovarian syndrome.Endocrinol Metab Clin North Am. 1988 Dec;17(4):785-813. Endocrinol Metab Clin North Am. 1988. PMID: 3143568 Review.
-
[Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate].Zhonghua Fu Chan Ke Za Zhi. 1999 Sep;34(9):528-32. Zhonghua Fu Chan Ke Za Zhi. 1999. PMID: 11360636 Chinese.
-
Induction of ovulation in the patient with polycystic ovarian disease.Endocrinol Metab Clin North Am. 1988 Dec;17(4):733-49. Endocrinol Metab Clin North Am. 1988. PMID: 3143566 Review.
-
Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.Int J Fertil Menopausal Stud. 1993 May-Jun;38(3):152-9. Int J Fertil Menopausal Stud. 1993. PMID: 8348163
Cited by
-
Generation of a mouse model with a reversible hypomorphic cytochrome P450 reductase gene: utility for tissue-specific rescue of the reductase expression, and insights from a resultant mouse model with global suppression of P450 reductase expression in extrahepatic tissues.J Pharmacol Exp Ther. 2010 Jul;334(1):69-77. doi: 10.1124/jpet.110.167411. Epub 2010 Apr 7. J Pharmacol Exp Ther. 2010. PMID: 20375200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical